These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 9151155)
61. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Kaplan AP; Joseph K Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213 [TBL] [Abstract][Full Text] [Related]
62. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Palcoux JB; Atassi-Dumont M; Lefevre P; Hequet O; Schlienger JL; Brignon P; Roussel B Ther Apher Dial; 2008 Jun; 12(3):195-201. PubMed ID: 18503695 [TBL] [Abstract][Full Text] [Related]
63. Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. Kohno M; Yokokawa K; Minami M; Yasunari K; Maeda K; Kano H; Hanehira T; Yoshikawa J Metabolism; 1999 Oct; 48(10):1256-9. PubMed ID: 10535387 [TBL] [Abstract][Full Text] [Related]
64. Apheresis technologies for prevention and regression of atherosclerosis: clinical results. Bambauer R; Schneidewind JM; Latza R ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615 [TBL] [Abstract][Full Text] [Related]
65. Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles. Wang JW; Zhang YN; Sze SK; van de Weg SM; Vernooij F; Schoneveld AH; Tan SH; Versteeg HH; Timmers L; Lam CSP; de Kleijn DPV Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29286309 [TBL] [Abstract][Full Text] [Related]
66. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Stefanutti C; Di Giacomo S; Vivenzio A; Isacchi GC; Masella R; Caprari P; Varì R; Tarzia A; Mosiello A; Cantafora A Clin Sci (Lond); 2001 Feb; 100(2):191-8. PubMed ID: 11171288 [TBL] [Abstract][Full Text] [Related]
67. High molecular weight kininogen: its inability to correct the clotting of kininogen-deficient plasma after cleavage of bradykinin by plasma kallikrein, plasmin or trypsin. Chan JY; Movat HZ; Burrowes CE Thromb Res; 1979; 14(6):817-24. PubMed ID: 157559 [No Abstract] [Full Text] [Related]
68. A simple and rapid method to study the association of the contact proteins of blood coagulation. Katcher HL; Samuel M; Villanueva GB Thromb Res; 1992 Dec; 68(6):443-50. PubMed ID: 1341054 [TBL] [Abstract][Full Text] [Related]
69. Experience with low-density lipoprotein apheresis by polyclonal and monoclonal anti-apolipoprotein B antibodies and by dextran sulfate cellulose. Riesen WF Curr Stud Hematol Blood Transfus; 1990; (57):208-19. PubMed ID: 2272202 [No Abstract] [Full Text] [Related]
70. Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis. Kojima S; Shida M; Tanaka K; Takano H; Yokoyama H; Kuramochi M Ther Apher; 2001 Feb; 5(1):2-6. PubMed ID: 11258604 [TBL] [Abstract][Full Text] [Related]
71. Contact phase of blood coagulation is not activated in edema of high altitude. Bärtsch P; Lämmle B; Huber I; Haeberli A; Vock P; Oelz O; Straub PW J Appl Physiol (1985); 1989 Oct; 67(4):1336-40. PubMed ID: 2793733 [TBL] [Abstract][Full Text] [Related]
72. Heparin-induced extracorporeal low-density lipoprotein precipitation and low-density lipoprotein chemoadsorption onto dextran sulfate: a comparison. Bosch Y Artif Organs; 1996 Apr; 20(4):328-31. PubMed ID: 9139618 [TBL] [Abstract][Full Text] [Related]
73. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Schettler V; Monazahian M; Wieland E; Thomssen R; Müller GA Ther Apher; 2001 Oct; 5(5):384-6. PubMed ID: 11778924 [TBL] [Abstract][Full Text] [Related]
75. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis. Davidson DC; Peart I; Turner S; Sangster M Lancet; 1994 Jun; 343(8912):1575. PubMed ID: 7911901 [No Abstract] [Full Text] [Related]
76. Heparin-free DALI LDL-apheresis in hyperlipidemic patients: efficacy, safety and biocompatibility. Wendler T; Lennertz A; Heinemann O; Duhr C; Samtleben W; Bosch T Int J Artif Organs; 2000 Oct; 23(10):710-7. PubMed ID: 11075902 [TBL] [Abstract][Full Text] [Related]
77. Use of losartan in FH patients during treatment with DSC-LDL apheresis. Pintus S; Pintus P; Maxia P; Anedda S J Clin Apher; 1997; 12(3):156. PubMed ID: 9365870 [No Abstract] [Full Text] [Related]
78. Unmasking hypotension by beta lactam during dextran sulfate low-density lipoprotein apheresis. Takenaka T; Sakamoto M; Suzuki H Am J Kidney Dis; 2004 Dec; 44(6):e107-8. PubMed ID: 15558512 [TBL] [Abstract][Full Text] [Related]
79. Apolipoprotein B-100 of plasma low density lipoproteins undergoes proteolysis by contact activation factors when plasma is treated with dextran sulfate-500-MgCl2. Byrne RE; Scanu AM J Lipid Res; 1989 Jan; 30(1):109-20. PubMed ID: 2465366 [TBL] [Abstract][Full Text] [Related]
80. A method of determination of human plasma HMW and LMW kininogen levels by bradykinin enzyme immunoassay. Uchida Y; Majima M; Katori M Pharmacol Res Commun; 1986 Sep; 18(9):831-46. PubMed ID: 3541001 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]